CYTO logo

Altamira Therapeutics (CYTO) Free Cash Flow

Annual FCF

-$614.50 K
+$11.06 M+94.74%

December 1, 2023

Summary

Performance

1-Year Change

+94.74%

3-Year Change

+92.5%

5-Year Change

+96%

15-Year Change

+97.55%

CYTO Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

79.58%
CYTO annual free cash flow is higher than 79.58% of companies in Healthcare sector

High & Low

All-time High

-$614.50 K
CYTO annual free cash flow is currently at an all-time high

3-Year Low

-$18.60 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
CYTO previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
CYTO next annual earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

Annual CFO

-$614.50 K
CYTO annual cash flow from operations is -$614.50 thousand

Annual CFF

$1.19 M
CYTO annual cash flow from financing activities is $1.19 million

Annual CFI

$2500.00
CYTO annual cash flow from investing activities is $2500.00

Annual CAPEX

-
CYTO annual capital expenditures value is unknown

Quarterly FCF

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.64 M
CYTO quarterly free cash flow is currently at an all-time high

3-Year Low

-
CYTO quarterly free cash flow 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

Quarterly CFO

-
CYTO quarterly cash flow from operations value is unknown

Quarterly CFF

-
CYTO quarterly cash flow from financing activities value is unknown

Quarterly CFI

-
CYTO quarterly cash flow from investing activities value is unknown

Quarterly CAPEX

-
CYTO quarterly capital expenditures value is unknown

TTM FCF

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.64 M
CYTO TTM free cash flow is currently at an all-time high

3-Year Low

-
CYTO TTM free cash flow 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

TTM CFO

-
CYTO TTM cash flow from operations value is unknown

TTM CFF

-
CYTO TTM cash flow from financing activities value is unknown

TTM CFI

-
CYTO TTM cash flow from investing activities value is unknown

TTM CAPEX

-
CYTO TTM capital expenditures value is unknown

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

-$614.50 K
CYTO annual free cash flow is -$614.50 thousand

Annual CFO

-$614.50 K
CYTO annual cash flow from operations is -$614.50 thousand

Annual CAPEX

-
CYTO annual capital expenditures value is unknown

CYTO Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+94.7%--
3 y3 years+92.5%--
5 y5 years+96.0%--

CYTO Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+96.7%
5 y5-yearat high+96.7%
alltimeall timeat high+97.9%

Altamira Therapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Dec 2023
-$614.50 K(-94.7%)
-
-
Dec 2022
-$11.68 M(-37.2%)
-
-
Dec 2021
-$18.60 M(+127.0%)
-
-
Dec 2020
-$8.19 M(-30.4%)
-
-
Dec 2019
-$11.78 M(-23.3%)
-
-
Dec 2018
-$15.36 M(-38.7%)
-$3.95 M(-3.4%)
-$15.46 M(-12.3%)
Sep 2018
-
-$4.09 M(+89.2%)
-$17.63 M(-6.6%)
Jun 2018
-
-$2.16 M(-58.8%)
-$18.88 M(-18.7%)
Mar 2018
-
-$5.25 M(-14.3%)
-$23.23 M(-6.3%)
Dec 2017
-$25.08 M(-14.0%)
-$6.13 M(+14.8%)
-$24.80 M(-0.8%)
Sep 2017
-
-$5.34 M(-18.1%)
-$24.99 M(-5.8%)
Jun 2017
-
-$6.52 M(-4.4%)
-$26.54 M(-10.3%)
Mar 2017
-
-$6.82 M(+7.9%)
-$29.60 M(-1.8%)
Dec 2016
-$29.15 M
-$6.32 M(-8.2%)
-$30.15 M(-1.6%)
Sep 2016
-
-$6.88 M(-28.2%)
-$30.65 M(-2.3%)
DateAnnualQuarterlyTTM
Jun 2016
-
-$9.58 M(+30.1%)
-$31.38 M(+2.4%)
Mar 2016
-
-$7.37 M(+8.0%)
-$30.65 M(+2.4%)
Dec 2015
-$29.14 M(+40.2%)
-$6.82 M(-10.4%)
-$29.94 M(+0.5%)
Sep 2015
-
-$7.61 M(-13.9%)
-$29.79 M(+19.8%)
Jun 2015
-
-$8.85 M(+32.9%)
-$24.86 M(+6.9%)
Mar 2015
-
-$6.65 M(-0.2%)
-$23.25 M(+3.4%)
Dec 2014
-$20.79 M(+30.3%)
-$6.67 M(+148.3%)
-$22.49 M(+9.2%)
Sep 2014
-
-$2.69 M(-62.9%)
-$20.60 M(-7.7%)
Jun 2014
-
-$7.24 M(+22.7%)
-$22.31 M(+14.2%)
Mar 2014
-
-$5.90 M(+23.5%)
-$19.53 M(+27.9%)
Dec 2013
-$15.95 M(+214.4%)
-$4.78 M(+8.6%)
-$15.27 M(+45.5%)
Sep 2013
-
-$4.40 M(-1.4%)
-$10.50 M(+72.1%)
Jun 2013
-
-$4.46 M(+172.9%)
-$6.10 M(+272.9%)
Mar 2013
-
-$1.64 M
-$1.64 M
Dec 2012
-$5.07 M
-
-

FAQ

  • What is Altamira Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Altamira Therapeutics?
  • What is Altamira Therapeutics annual FCF year-on-year change?
  • What is the all time high quarterly FCF for Altamira Therapeutics?
  • What is the all time high TTM FCF for Altamira Therapeutics?

What is Altamira Therapeutics annual free cash flow?

The current annual FCF of CYTO is -$614.50 K

What is the all time high annual FCF for Altamira Therapeutics?

Altamira Therapeutics all-time high annual free cash flow is -$614.50 K

What is Altamira Therapeutics annual FCF year-on-year change?

Over the past year, CYTO annual free cash flow has changed by +$11.06 M (+94.74%)

What is the all time high quarterly FCF for Altamira Therapeutics?

Altamira Therapeutics all-time high quarterly free cash flow is -$1.64 M

What is the all time high TTM FCF for Altamira Therapeutics?

Altamira Therapeutics all-time high TTM free cash flow is -$1.64 M